Opium is one of the world's oldest drugs, and its derivatives morphine and codeine are among the most used clinical drugs to relieve severe pain. These prototypical opioids produce analgesia as well as many undesirable side effects (sedation, apnoea and dependence) by binding to and activating the G-protein-coupled m-opioid receptor (m-OR) in the central nervous system. Here we describe the 2.8 Å crystal structure of the mouse m-OR in complex with an irreversible morphinan antagonist. Compared to the buried binding pocket observed in most G-protein-coupled receptors published so far, the morphinan ligand binds deeply within a large solvent-exposed pocket. Of particular interest, the m-OR crystallizes as a two-fold symmetrical dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6. These high-resolution insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.
Opium is one of the world's oldest drugs, and its derivatives morphine and codeine are among the most used clinical drugs to relieve severe pain. These prototypical opioids produce analgesia as well as many undesirable side effects (sedation, apnoea and dependence) by binding to and activating the G-protein-coupled m-opioid receptor (m-OR) in the central nervous system. Here we describe the 2.8 Å crystal structure of the mouse m-OR in complex with an irreversible morphinan antagonist. Compared to the buried binding pocket observed in most G-protein-coupled receptors published so far, the morphinan ligand binds deeply within a large solvent-exposed pocket. Of particular interest, the m-OR crystallizes as a two-fold symmetrical dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6. These high-resolution insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.
Opium extracts from the plant Papaver somniferum have been used for therapeutic and recreational purposes for thousands of years. Opioid alkaloids and related pharmaceuticals are the most effective analgesics for the treatment of acute and chronic pain. They also represent one of the largest components of the illicit drug market worldwide, generating revenue of approximately $70 billion in 2009, much of which supports crime, wars and terrorism (UNODC World Drug Report 2011). Intravenous use of opioid drugs is a leading cause of death by overdose in Europe and North America, and a major contributing factor to the worldwide AIDS epidemic.
Morphine and codeine are the main active opioid alkaloids in opium. In humans, they act on the central nervous system to produce a wide range of effects including analgesia, euphoria, sedation, respiratory depression and cough suppression, and have peripheral effects such as constipation 1 . Gene disruption studies in mice show that the target for the majority of the effects of opioid alkaloids, whether beneficial or adverse, is the m-OR 2 . The m-OR belongs to the c subfamily of class A G-protein-coupled receptors (GPCRs) with two closely related family members known as the dand k-opioid receptors 3 . The m-OR constitutes the main opioid target for the management of pain, acute pulmonary oedema, cough, diarrhoea and shivering 1 . However, opioid drugs are highly addictive, with the acetylated form of morphine, heroin, being the best-known example. Because of this, the clinical efficacy of opioid drugs is often limited by the development of tolerance and dependence.
Although both beneficial and adverse effects are attributable to activation of the m-OR, they seem to be mediated by different downstream signalling and regulatory pathways. The m-OR couples predominantly to Gi, the inhibitory G protein for adenylyl cyclase. m-OR signalling through Gi is responsible for its analgesic properties 4 . After activation, the m-OR undergoes phosphorylation and subsequently couples to arrestins, which have both regulatory and signalling functions 5 . Studies suggest that ligands with the greatest addictive potential, such as morphine, promote interactions with Gi more strongly than they promote interactions with arrestins 6 . These studies suggest that it may be possible to develop safer and more effective therapeutic agents targeting the m-OR.
To understand better the structural basis for m-OR function, we performed a crystallographic study of this receptor using the T4 lysozyme (T4L) fusion protein strategy developed previously 7 ( Supplementary  Fig. 1 ). Using the in meso crystallization method, we obtained crystals and collected diffraction data from 25 crystals of Mus musculus m-OR-T4L protein bound to the irreversible morphinan antagonist b-funaltrexamine (b-FNA). The structure was solved by molecular replacement from a 2.8 Å data set.
Transmembrane architecture
The lattice for the m-OR receptor shows alternating aqueous and lipidic layers with receptors arranged in parallel dimers tightly associated through transmembrane (TM) helices 5 and 6. More limited parallel interdimeric contacts through TM1, TM2 and helix 8 are observed between adjacent dimers ( Supplementary Fig. 2 ).
As in other GPCRs, the structure of the m-OR consists of seven TM a-helices that are connected by three extracellular loops (ECL1-3) and three intracellular loops (ICL1-3) ( Fig. 1a ). TM3 is connected to ECL2 by a conserved disulphide bridge between C140 3.25 (superscripts indicate Ballesteros-Weinstein numbers 8 ) and C217. The morphinan ligand b-FNA ( Fig. 1b , c) makes contacts with TM3, TM5, TM6 and TM7 (Fig. 1a ), and the electron density observed in the structure confirms previous data identifying the K233 5.39 side chain as the site of covalent attachment 9 ( Fig. 1c and Supplementary Fig. 3 ).
The intracellular face of the m-OR closely resembles rhodopsin with respect to the relative positions of TM3, TM5 and TM6 (Supplementary Fig. 4 ). Nevertheless, like the b 2 -adrenergic receptor (b 2 -AR), there is no ionic bridge between the DRY sequence in TM3 and the cytoplasmic end of TM6. As with the b 2 -AR, R165 3.50 forms a salt bridge with the adjacent D164 3.49 of the DRY sequence. D164 3.49 also engages in a polar interaction with R179 in ICL2, a feature that is similar to an interaction observed between D130 3.49 and S143 in ICL2 of the b 2 -AR ( Supplementary Fig. 4 ). In the m-OR, it has been shown that the mutation of T279 6.34 to a lysine results in a constitutively active receptor 10 . This may be explained by a polar interaction observed in the crystal structure of the m-OR between T279 6.34 and R165 3.50 ( Supplementary Fig. 4 ). This interaction may stabilize the receptor in an inactive state.
An exposed ligand-binding pocket
In most available GPCR structures, the ligand is partially buried within the helical bundle by more superficial residues in TM segments and ECL2. The most extreme examples are the M2 and M3 muscarinic receptors 11, 12 , in which the ligand is covered with a layer of tyrosines ( Fig. 2 ). This provides a structural basis for the very slow dissociation 90°T   M1   TM2   TM3   ECL1   ECL2   ECL3   TM4   TM5   TM7   TM6   TM1  TM2   TM3   ICL1   ICL2   Helix 8   TM4   TM5   TM7  TM6   Intracellular   Extracellular   TM1   TM2 M2   ECL1   ECL2   ECL3   T TM3 M3   TM5   TM7 
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kinetics of muscarinic antagonists. For example, the dissociation halflife of the clinically used drug tiotropium at the M3 receptor is 34.7 h and its dissociation constant (K d ) is 40 pM (ref. 13) . By contrast, the binding pocket for b-FNA in the m-OR is largely exposed to the extracellular surface ( Fig. 2a ). This may explain why extremely potent opioids such as buprenorphine, with an inhibition constant (K i ) of 740 pM, diprenorphine (K i 72 pM), alvimopan (K i 350 pM) and etorphine (K i 230 pM) present rapid dissociation half-lives of 44 min, 36 min, 30 min 14 and less than 1 min (ref. 15 ), respectively. Therefore, although the affinity of high-affinity opioid ligands is comparable to tiotropium, the dissociation kinetics are considerably different. This feature of opioid ligands may explain why heroin overdoses are rapidly reversible by naloxone 16 . In addition, the extremely high potency and fast kinetics of etorphine agonism and diprenorphine antagonism allows for a system that is capable of rapid anaesthesia and prompt reversal in veterinary use. As a result, etorphine is a preferred anaesthetic (dose in the range of 5-20 mg kg 21 ) for valuable racehorses and for captive and free-ranging mammals 17 .
The m-OR belongs to a subgroup of peptide GPCRs, and the closest published structure is that of the CXCR4 chemokine receptor 18 (root mean squared deviation (r.m.s.d.) value of 1.35 Å ). In the m-OR the morphinan ligand b-FNA binds much more deeply than the smallmolecule CXCR4 antagonist IT1t and occupies a similar position as agonists and antagonists for the b 2 -AR (r.m.s.d. value of 1.52 Å ) and other monoamine receptors ( Fig. 2c ).
Binding pocket and opioid specificity
There are 14 residues within 4 Å of b-FNA. Nine of these have more direct interactions with the ligand (Fig. 3a-c) , and are conserved in the k-OR and d-OR. D147 3.32 engages in a charge-charge interaction with the amine moiety of the ligand and hydrogen bonds with Y326 7.43 (both residues are strictly conserved in all the opioid receptor subtypes). Although D147 3.32 occupies the same position as the counterion in aminergic receptors, a sequence comparison shows that it is not conserved in other peptide receptors. H297 6.52 interacts with the aromatic ring of the morphinan group, but does not directly hydrogen bond with b-FNA as has been previously suggested 19 . However, the electron density suggests the presence of two water molecules that are well positioned to form a hydrogen-bonding network between H297 6.52 and the phenolic hydroxyl of the morphinan group (Fig. 3b, c) .
A direct comparison with the d-OR sequence also shows that of the 14 residues within 4 Å of the ligand, 11 are identical between m-OR and d-OR. The three differences are at m-OR positions E229 ECL2 , K303 6.58 and W318 7.35 , which are Asp, Trp and Leu in the d-OR, respectively. The substitution of leucine in d-OR for W318 7.35 is highlighted in Fig. 3d . W318 7.35 was shown to be responsible for the binding selectivity of naltrindole, a d-OR-selective antagonist and of [D-Pen2,D-Pen5]enkephalin (DPDPE), a d-OR-selective peptide agonist 20 . In particular, the point mutation W318L markedly increases the affinity of both these ligands at the m-OR. Positioning naltrindole (represented in Fig. 3d) bound to the receptor through K233 5.39 (bold). Hydrophobic interactions are shown in orange and polar contacts with red dotted lines. V300 6.55 and I296 6.51 form extensive hydrophobic contacts with the back face of the ligand (not shown). Two water molecules are positioned between H297 6.52 and the phenolic group of b-FNA. d, The d-OR-selective ligand naltrindole includes an indole group that would clash with W318 7.35 in m-OR, but not with the leucine found in the equivalent position in d-OR. The indole has been described as an 'address' to target the ligand to d-OR, whereas its efficacy ('message') is determined by the morphinan group on the left 40 .
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superimposition of its morphinan group on that of b-FNA shows that naltrindole would clash with the W318 side chain in m-OR ( Fig. 3d ), whereas the leucine in this position of d-OR would probably accommodate naltrindole without requiring structural rearrangement. Endomorphins 1 and 2 are small peptides isolated from brain that were shown to have the highest affinity (low nM range) and the highest selectivity profile for the m-OR receptor 21 . For instance, endomorphin 1 exhibits 4,000-and 15,000-fold selectivity for m-OR over d-OR and k-OR, respectively 21 . Although little is known about the determinants of endomorphin binding, mutagenesis studies suggest that the m-OR-selective synthetic peptide agonist [D-Ala2,N-MePhe4,Gly-ol5] enkephalin (DAMGO) occupies a space that overlaps with the b-FNA-binding pocket but also extends beyond this site 22 . Sites of mutations that impair DAMGO binding include H297 6.52 , positioned near the bottom of the b-FNA pocket, as well as K303 6.58 , W318 7.35 and H319 7.36 , positioned above the b-FNA-binding pocket (Supplementary Fig. 5 ). Given the residues involved in DAMGO binding to m-OR, opioid peptides probably make both polar and non-polar contacts within the m-OR-binding pocket. This feature of opioid peptide binding is also reflected in the lack of a highly charged surface within the m-OR-binding pocket compared with that of the CXCR4 receptor 18 .
Oligomeric arrangement of m-OR
The structure of m-OR shows receptor molecules intimately associated into pairs along the crystallographic two-fold axis through two different interfaces (Fig. 4a, b ). The first interface is a more limited parallel association mediated by TM1, TM2 and helix 8, with a buried surface area of 615 Å 2 ( Fig. 4d and Supplementary Fig. 6 ). The second and more prominent interface observed in the m-OR crystal structure is comprised of TM5 and TM6 (Fig. 4c ). In this case, within each m-OR-m-OR pair, the buried surface area for a single protomer is 1,492 Å 2 . This represents 92% of the total buried surface between m-OR-T4L molecules, indicating that the comparatively small 114 Å 2 buried surface contributed by T4L is unlikely to drive the contact ( Supplementary Fig. 7 ). This suggests that the pairwise association of receptor monomers may represent a physiological opioid receptor dimer or higher-order oligomer, the existence of which is supported by previous biochemical, pharmacological and cell biological studies 23 .
Recent computational and biochemical studies have indicated the potential role of TM4 and TM5 in the interaction between d-OR receptors 24 . More generally, oligomers have been observed for a large number of GPCRs (recently reviewed in ref. 25) . Some of these studies have shown that TM5 and TM6 peptides can disrupt dimers of the b 2 -AR and V2 vasopressin receptor 26, 27 , and recent crosslinking experiments with the M3 muscarinic receptor suggest a direct dimeric contact mediated by TM5 of each monomer 28 . The potential involvement of the alternative TM1-TM2-H8 (where H8 is helix 8) interface in GPCR oligomerization has previously been indicated by several different biochemical studies 25 and, more recently, by the structure of opsin (Protein Data Bank (PDB) accession 3CAP) 29 . In the case of opioid receptors, it has been shown that a m-OR TM1 domain fused to a polybasic TAT sequence could disrupt the m-OR-d-OR interaction in the mouse spinal cord, resulting in an enhancement of morphine analgesia and a reduction in morphine tolerance 30 .
The more prominent interface observed in the m-OR crystal structure is comprised of TM5 and TM6 of each protomer arranged in a four-helix bundle motif (Fig. 5a ). This interface is formed by an extensive network of interactions involving 28 residues in TM5 and TM6 ( Fig. 5c and Supplementary Fig. 8 ). These surface packing interactions are highly complementary and are maintained all along the receptor membrane plane from the extracellular to the intracellular side of the m-OR (Fig. 5c, d) . The T279 6.34 residue described earlier as having a role in maintaining the receptor in an inactive state is also part of the dimer interface, with the methyl of the threonine contacting I256 5.62 of the adjacent protomer. It is thus tempting to speculate that dimerization of the m-OR could have a role in regulating receptor signalling.
The observed dimer is of interest because of existing evidence for both homo-and heterodimers (or oligomers) involving the m-OR 31 . It has been suggested that opioid agonists such as DAMGO and methadone reduce tolerance to morphine in vivo by facilitating morphine-induced endocytosis through m-OR oligomerization 32, 33 . These studies implicate allosteric interactions between a protomer bound to DAMGO or methadone and an adjacent protomer bound to morphine. Co-expressing m-OR and d-OR in cells results in pharmacological profiles distinct from either receptor expressed alone 34 . Of interest, morphine is more efficacious in cells expressing both m-OR and d-OR in the presence of a d-OR-selective antagonist, suggesting an allosteric interaction between m-OR and d-OR protomers 35 . Hetero-oligomerization between m-OR and non-opioid receptors has RESEARCH ARTICLE also been reported 23 . For example, the a 2a adrenergic receptor was shown to modulate receptor m-OR structure and signalling 36 . Consistent with a role for oligomerization in m-OR function, we observed that the amino acids involved in the dimer interface display a high degree of homology with the d-OR ( Supplementary Figs 9 and  10 ). Replacing the residues of m-OR with the corresponding residues from d-OR would not be predicted to interfere with dimer formation ( Supplementary Figs 9 and 10 ). This analysis also suggests that a m-OR-d-OR dimer could share the same interface. Interestingly, in the m-OR TM5-TM6 dimer, the two binding sites are coupled through a network of packing interactions at the dimeric interface (Fig. 5b ). This network could provide a structural explanation for the distinct pharmacological profiles obtained for m-OR heterodimers and for the allosteric effects of one protomer on the pharmacological properties of the other. This dimeric interface thus provides potential insights into the mechanism of allosteric regulation of one GPCR protomer by the other.
Parallel dimers have also been observed in other GPCR crystal structures, most notably in CXCR4-T4L 18 . Interestingly, the CXCR4 dimer is also related by a two-fold rotational symmetry axis with a receptor arrangement similar but not identical to that seen in m-OR ( Supplementary Fig. 8 ). However, for the five different CXCR4-T4L crystal structures, the largest calculated contact area between the two CXCR4 protomers is smaller (1,077 Å 2 for PDB accession 3OE0) than in the m-OR structure ( Supplementary Fig. 7) , and it presents a comparatively less extensive network of interactions ( Supplementary  Fig. 8 ).
The dimeric arrangement of m-OR across the TM5-TM6 interface observed in the crystal structure would probably preclude either protomer from coupling to G proteins. This is based on structural changes in TM5 and TM6 observed in the recent crystal structure of the b 2 -AR-G s complex 37 . This is also consistent with the observation that inverse agonists stabilize b 2 -AR oligomers, while the G protein G s reduced the extent of oligomerization 38 . However, we were able to model an active structure of m-OR in complex with G protein based on the crystal structure of the b 2 -AR-G s complex. Here, we observed that a tetramer formed by the association of two dimers through a TM5-TM6 interface would accommodate two G proteins in interaction with the two distal protomers ( Supplementary Fig. 11 ). This model of an activated m-OR-G-protein oligomeric complex is highly speculative but is compatible with results from a recent biophysical study suggesting that the G-protein G i remains associated with a m-OR tetramer stabilized by the agonist morphine 39 .
The m-OR is perhaps the most economically important GPCR in terms of the combined legal and illicit drug market. Although there are a number of effective drugs targeting the m-OR on the market, the ideal agonist has yet to be developed. The structure of the m-OR presented here provides the first high-resolution insight, to our knowledge, into a peptide receptor that can also be activated by small-molecule agonist ligands, some of which are the oldest used drugs in human history. This structure will enable the application of structure-based approaches to complement more conventional drug discovery programs. In addition, it may provide novel insights into the role of oligomerization in GPCR function.
METHODS SUMMARY
The m-OR-T4L fusion protein was expressed in Sf9 insect cells and purified by nickel affinity chromatography followed by Flag antibody affinity chromatography and size-exclusion chromatography. It was crystallized using the lipidic cubic phase technique, and diffraction data were collected at GM/CA-CAT beamline 23ID-D at the Advanced Photon Source at Argonne National Laboratory. The structure was solved by molecular replacement using merged data from 25 crystals. 
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